REMARKS

Applicants have amended the specification to indicate the application's priority information. Applicants have also amended claims 1-6 and 10-11 to conform the claims to U.S. practice.

No new matter has been added by these amendments.

If there are any other charges, or any credits, please apply them to Deposit Account No. 03-2095.

Respectfully submitted,

KALEN L. ECBING SEGNO 35, 238 POR ady, Ph.D.

Clark & Elbing LLP 101 Federal Street

Boston, MA 02110-2214

Telephone: 617-428-0200 Facsimile: 617-428-7045

F:\50125\114xxx\50125.114001 Preliminary Amendment with National Phase application.doc

Exhibit 2



NEW US PATENT A	PPLICATION	N Attorney Docket Num	ber: 50125/114001
The U.S. PTO date stamp sets forth the date of receipt and serial number of new U.S. Patent application:			
Applicant: Carsten Hopf et al.			
Title: TREATMENT OF NEURODEGENERATIVE DISEASES BY THE USE OF ATP7A			
▼ Transmittal	Pages: 2	☐ Assignment & Cover Sheet	Pages:
Application Data Sheet	Pages: 4	☑ Preliminary Amendment	Pages: ' <u>. 5</u>
☑ Published Application	Pages: 31	□ IDS	Pages:
☑ PCT/RO/101	Pages: 2	☐ Cited References	Number:
☑ PCT/ISA/210 & 237	Pages: 8	☐ Form PTO-1449	Pages:
☑ PCT/IB/301, 304 & 308	Pages: 5	☐ Sequence Listing	Pages:
☐ Drawings	Pages:	☐ Sequence Statement	Pages:
☐ Declaration & POA	Pages:	☐ Sequence Diskette	Number:
☑ Check	\$: <u>1030.</u>	Other	Pages:
EXPRESS MAIL LABEL: EV2542	05135US	0/587426	
Atty/Secv: KRR: KLF:cal	Matter Name	e: CEI 63160PCUS Dat	e: 07/26/06

IMP13 Rac'd PET/PTO 26 JUL 2006